Attenuation of toll-like receptor 2-mediated innate immune response in patients with alcoholic chronic liver disease

Liver Int. 2010 Aug;30(7):1003-11. doi: 10.1111/j.1478-3231.2010.02251.x. Epub 2010 May 13.

Abstract

Background: Alcoholic chronic liver disease (ACLD) is a common form of acquired immunodeficiency.

Aim: To evaluate ex vivo toll-like receptor (TLR) 2 and TLR4 innate immune response in stable ACLD.

Methods: Blood was collected from 26 males with stable ACLD and from 17 controls. Serum was used for lipopolysaccharide (LPS), sCD14, LPS-binding protein (LBP), tumour necrosis factor-alpha (TNF-alpha) and interleukin 10 (IL-10) quantification. Peripheral blood monocytes (PBM) protein expression of TLR2 and TLR4 was determined by flow cytometry. Primary cultures of anti-CD11b positive selected PBM were stimulated with the TLR2/TLR6 ligand zymosan (Zym), with TLR2/TLR1 ligand lipopeptide (Lp) and with TLR4 ligand LPS. PBM TLR1, TLR2, TLR4, TLR6, MD2, CD14, TNF-alpha and IL-10 gene expression was evaluated by reverse transcription-polymerase chain reaction.

Results: Stable ACLD patients showed increased circulating LPS (+22.5+/-4.1%), LBP (+60.6+/-12.2%) and sCD14 (+23.5+/-4.6%), with no differences in TNF-alpha and IL-10. Zym and Lp, but not LPS, induced TNF-alpha production by monocytes was blunted in ACLD (-66+/-20.4% Zym; -40.1+/-13.5% Lp; P<0.05). Basal TNF-alpha mRNA expression was decreased in PBM from ACLD patients (-50.1+/-21.0%; P<0.05), with no significant differences in the other studied genes. Results were similar in Child-Pugh A and B/C patients.

Conclusions: Patients with stable ACLD show an attenuation of TLR2-mediated innate immune response in PBM, which may represent an important mechanism for acquired immunodeficiency. This was neither related with decreased TLR2 or its co-receptors expression nor with impaired TLR4 activation, being already present in the early stages of disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute-Phase Proteins
  • Carrier Proteins / blood
  • Case-Control Studies
  • Cells, Cultured
  • Chronic Disease
  • Down-Regulation
  • Gene Expression Profiling
  • Humans
  • Immunity, Innate* / genetics
  • Interleukin-10 / blood
  • Leukocytes, Mononuclear / drug effects
  • Leukocytes, Mononuclear / immunology*
  • Lipopeptides / pharmacology
  • Lipopolysaccharide Receptors / blood
  • Lipopolysaccharides / pharmacology
  • Liver Diseases, Alcoholic / immunology*
  • Male
  • Membrane Glycoproteins / blood
  • Middle Aged
  • Portugal
  • RNA, Messenger / metabolism
  • Toll-Like Receptor 2 / agonists
  • Toll-Like Receptor 2 / blood*
  • Toll-Like Receptor 2 / genetics
  • Toll-Like Receptor 4 / blood
  • Tumor Necrosis Factor-alpha / blood
  • Zymosan / pharmacology

Substances

  • Acute-Phase Proteins
  • Carrier Proteins
  • IL10 protein, human
  • Lipopeptides
  • Lipopolysaccharide Receptors
  • Lipopolysaccharides
  • Membrane Glycoproteins
  • RNA, Messenger
  • TLR2 protein, human
  • TLR4 protein, human
  • Toll-Like Receptor 2
  • Toll-Like Receptor 4
  • Tumor Necrosis Factor-alpha
  • lipopolysaccharide-binding protein
  • Interleukin-10
  • Zymosan